Oncology Biomarker Diagnostics

Linking molecular status to breakthroughs in cancer treatment

Assay Menu By Pathway

MolecularMD employs gold-standard and cutting-edge Technologies & Platforms in creating its high-performance assays. Below are listed our validated research and diagnostic assays. For information about other biomarkers and custom assay design capabilities, contact MolecularMD.

MEK Pathway Analysis

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate MEK Pathways Analysis and potential monitoring of treatment efficacy.

  • BRAF Mutation (Exon 15)
  • BRAF Mutation (V600E/K)
  • KRAS Mutation (G12D/A/V/S/R, G13D, Q61L/R/H)
  • NRAS Mutation (Exons 1, 2)
  • NRAS Mutation (Q61R/K/L)
  • phospho ERK Thr202/Tyr204 Analysis

This email address is being protected from spambots. You need JavaScript enabled to view it.

PI3K/mTOR Pathway Analysis

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate PI3K/mTOR Pathways Analysis and potential monitoring of treatment efficacy.

  • PIK3CA Mutation (Exons 1, 5, 7, 9 , 20)
  • PIK3CA Gene Amplification
  • PTEN Expression
  • PTEN Mutation (Exons 5, 6, 7, 8)
  • phospho AKT Ser473 Analysis
  • total AKT Expression Analysis
  • phospho S6 Ser235/236 Analysis
  • phospho S6 Ser240/244 Analysis

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tumor Suppressor Gene Analysis

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate Tumor Suppressor Gene Analysis and potential monitoring of treatment efficacy.

  • LKB1 Mutation
  • PTEN Mutation (Exons 5, 6, 7, 8)
  • PTEN Expression

This email address is being protected from spambots. You need JavaScript enabled to view it.

Related Services:

Oncology Thought Leaders Series:
Brian Druker, MD speaks on the value of
companion diagnostics in patient outcomes